Overview

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Status:
Completed
Trial end date:
2020-07-22
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug ixekizumab is safe and effective in participants with generalized pustular psoriasis and erythrodermic psoriasis.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ixekizumab